Author is bullish on Novocure, citing a new FDA-approved pancreatic cancer treatment as a needed new revenue source after revenue target beats.
NVCR — LONG The author argues Novocure has been declining but is turning the corner after beating revenue targets, and that its newly FDA-approved pancreatic cancer treatment is a massive new revenue source the company needed. The catalyst is the FDA approval and a medical director already prescribing it, with the benefit framed as reduced pain and fatigue and roughly two extra months of life. The main risk implied is skepticism that two months of added survival is meaningful, which the author counters from personal experience.
$NVCR have been needing a new revenue source to turn the corner and frankly this treatment is massive for pancreatic cancer.